Navigation Links
ThromboGenics Completes Patient Enrolment in US Phase III Trial of Microplasmin for the Non-Surgical Treatment of Eye Disease
Date:9/23/2009

LEUVEN, Belgium, September 24 /PRNewswire-FirstCall/ --

- Enrolment of 326 Patients Completed Ahead of Schedule

ThromboGenics NV (Euronext Brussels: THR), a biopharmaceutical company focused on the discovery and development of innovative treatments for eye disease, vascular disease and cancer, announces today that it has completed the enrolment of the US Phase III trial evaluating microplasmin for the non-surgical treatment of eye disease. The trial TG-MV-006 has completed enrolment with a total of 326 patients several months ahead of schedule. The second Phase III study with microplasmin, TG-MV-007, which is recruiting patients in the US and Europe is due to complete enrolment in the first half of 2010 as planned. Enrolment completion in this study means that ThromboGenics is a step closer to becoming a profitable, integrated Company focused on cutting edge ophthalmic medicines.

Microplasmin's Phase III program is referred to as the MIVI-TRUST (Microplasmin for IntraVitreous Injection-Traction Release without Surgical Treatment) program. This program involves two clinical trials, which are taking place in the United States (TG-MV-006 trial) and Europe and the United States (TG-MV-007 trial). Both of the MIVI-TRUST trials are multi-center, randomized, placebo controlled, double-masked trials which are evaluating 125microg of microplasmin versus placebo in the intravitreal treatment of patients with focal vitreomacular adhesion.

The initial indication for both of the Phase III microplasmin trials is the non-surgical treatment of focal vitreomacular adhesion. Focal vitreomacular adhesion is a condition in which the vitreous gel, in the center of the eye, has an abnormally strong adhesion to the retina at the back of the eye. Vitreomacular adhesion is thought to play a key role in numerous back of the eye conditions such as macular hole formation, and some forms of macular edema.
'/>"/>

SOURCE ThromboGenics NV
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. ThromboGenics Completes Patient Enrolment in the Phase IIb Trial of Microplasmin in Vitrectomy (MIVI III)
2. ThromboGenics Announces Promising Results of MITI IV Phase II Trial in the Treatment of Acute Stroke with Microplasmin
3. ThromboGenics Begins Phase III Program With Microplasmin for the Non-surgical Treatment of Back of the Eye Disease
4. ThromboGenics and BioInvent Receive Technology Transfer Success Fee From Roche for the Novel Anti-Cancer Antibody, TB-403 (Anti-PIGF)
5. ThromboGenics Completes Patient Enrolment for Phase II Trial of Microplasmin for the Treatment of Diabetic Macular Edema (MIVI II DME)
6. ThromboGenics Microplasmin Phase III Program Progressing According to Schedule
7. ThromboGenics and BioInvent Start Recruitment of Second 100 Patient Cohort in Phase II DVT Prophylaxis Study With TB-402
8. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
9. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
10. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
11. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2015)... 22, 2015 The leading companies in ... global cardiac rhythm management device market dominate their ... Medtronic, St. Jude Medical, Boston Scientific and Asahi ... market segment. The healthcare market research publisher,s report, ... 2015 as a base year, providing forecasts for ...
(Date:5/22/2015)...  The U.S. Food and Drug Administration,s (FDA) ... biosimilar product approved in the United ... the contract manufacturing organization (CMO) industry, according to ... to the production of small-molecular drugs and lacks ... healthcare market research publisher,s report, Biopharmaceutical and ...
(Date:5/22/2015)... 2015  The Mesothelioma Victims Center is incredibly ... get the best possible compensation, and they are also ... rare cancer caused by exposure to asbestos or ... to treatment options such as a recent possible ... Victims Center anytime at 866-714-6466. http://MesotheliomaVictimsCenter.Com ...
Breaking Medicine Technology:Kalorama: Top Companies Dominate Cardiac Defibrillator Market 2Kalorama: Top Companies Dominate Cardiac Defibrillator Market 3Kalorama: Top Companies Dominate Cardiac Defibrillator Market 4Kalorama: First FDA-Approved Biosimilar Brings Hope for CMO Growth 2Kalorama: First FDA-Approved Biosimilar Brings Hope for CMO Growth 3Kalorama: First FDA-Approved Biosimilar Brings Hope for CMO Growth 4Mesothelioma Victims Center Calls Attention to a Recent Medical Article About a New Drug That Could Slow the Progression of Mesothelioma and Allow People to Live Longer 2Mesothelioma Victims Center Calls Attention to a Recent Medical Article About a New Drug That Could Slow the Progression of Mesothelioma and Allow People to Live Longer 3Mesothelioma Victims Center Calls Attention to a Recent Medical Article About a New Drug That Could Slow the Progression of Mesothelioma and Allow People to Live Longer 4Mesothelioma Victims Center Calls Attention to a Recent Medical Article About a New Drug That Could Slow the Progression of Mesothelioma and Allow People to Live Longer 5
(Date:5/22/2015)... The American College of Traditional Chinese ... They will hold a webinar on the updates of ... on Classical Chinese Medicine. , Webinar – First Professional ... the Dean of Clinical Education, will lead this webinar ... Doctorate program. ACTCM is currently developing this degree program ...
(Date:5/22/2015)... New York, New York (PRWEB) May 22, 2015 ... ( http://www.xareltolawsuit2015.com/ ) filed on behalf of individuals ... complications due to its use continue to move ... of Louisiana. According to a Pretrial Order dated ... governing the preservation of documents and electronically stored ...
(Date:5/22/2015)... 2015 Combination therapy, or polytherapy, ... chronic obstructive pulmonary disorder (COPD) as the dominant ... plc as well as Germany’s Boehringer Ingelheim compete ... But will market payers, clinicians and patients be ... to completely new ones? , In spite of ...
(Date:5/22/2015)... Family, friends, students, colleagues, mentors and fellow physicians ... D. Leffall, on Monday, May 18, with an 85th ... in the hospital’s Tower Auditorium. Leffall’s younger sister, 83-year-old ... to keep the secret. “I’d like to go in ... know something is up,” she said. , After more ...
(Date:5/22/2015)... Memorial Day weekend is typically considered the beginning of vacation ... to help promote safe travel. , According to estimates from ... this Memorial Day weekend. Amica is sharing the following road ... , , Always wear a seatbelt: Make ... they’re driving or riding along as a passenger. Seatbelts are ...
Breaking Medicine News(10 mins):Health News:ACTCM Announces Upcoming June Events 2Health News:Court Overseeing Federal Xarelto Lawsuits Establishes Procedures Governing Preservation of Documents, Electronically Stored Information 2Health News:Court Overseeing Federal Xarelto Lawsuits Establishes Procedures Governing Preservation of Documents, Electronically Stored Information 3Health News:Court Overseeing Federal Xarelto Lawsuits Establishes Procedures Governing Preservation of Documents, Electronically Stored Information 4Health News:Chronic Obstructive Pulmonary Disorder Therapeutics Market Discussed in In-demand FirstWord Report Published at MarketPublishers.com 2Health News:Colleagues Surprise Dr. LaSalle Leffall with 85th Birthday Celebration 2Health News:Amica Has 4 Road Safety Tips for Memorial Day Weekend 2
... , MONDAY, Nov. 22 (HealthDay News) -- Infants with ... at high risk for heart and lung disorders that increase their ... analyzed the medical records of more than 50,000 very low birth ... at birth. They found that among this group of babies, those ...
... current staging system that determines the extent or severity ... online in CANCER , a peer-reviewed journal of ... is no link between localized prostate cancer,s clinical stage ... his prostate removed. One of the primary purposes ...
... discovered 30 new genes that control the age of ... also act on body weight regulation or biological pathways ... Nature Genetics , was a collaborative effort by ... 104 worldwide institutions, including Boston University School of Medicine ...
... African Americans with kidney disease related to hypertension (high ... a sharply increased risk of progressive kidney disease, according ... Nephrology,s 43rd Annual Meeting and Scientific Exposition. End Stage ... African American population at a rate 13.1 times greater ...
... Kidneys ,Kidney Donations by the Poor Are on the ... low incomes are more likely to develop kidney failure and ... people of other socioeconomic classes. Because fewer individuals in the ... University of British Columbia, in Vancouver, Canada) and colleagues examined ...
... in Fruits and Vegetables ,Healthy Foods Can Help Maintain ... disease, the Western diet produces an acidic environment in the ... as kidney function declines. Nimirit Goraya, MD (Texas A&M College ... conducted a study to see if consuming a diet high ...
Cached Medicine News:Health News:Tiniest Newborns With Down Syndrome Face Other Health Risks 2Health News:Genes link puberty timing and body fat in women 2Health News:Gene linked to worsening kidney disease in African-Americans 2Health News:Efforts needed to address disparities in kidney transplantation 2Health News:Efforts needed to address disparities in kidney transplantation 3Health News:Efforts needed to address disparities in kidney transplantation 4Health News:Kidneys: Produce-rich diet improves long-term health, melatonin improves short-term health 2Health News:Kidneys: Produce-rich diet improves long-term health, melatonin improves short-term health 3
Meter Trax Control is a whole blood quality control that can be used for glucose, hemoglobin and hematocrit testing on point of care instruments....
Lyphochek® Hemoglobin A1C Linearity Set is a human whole blood based product designed to verify linearity throughout the patient reportable range of hemoglobin A1C assays....
Liquichek Reticulocyte Control is a human whole blood based control designed to monitor manual and automated methods for counting reticulocytes. Assayed values are provided at three clinically signif...
Seroconversion and Antigen Panel Chart...
Medicine Products: